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                                Neuroblastoma, a tumor of the sympathetic nervous system, is the 
most common childhood extracranial solid tumor, accounting for 
8%  –  10% of childhood cancers and 15% of childhood cancer 
deaths (  1  ). Neuroblastomas demonstrate clinical heterogeneity, 
from spontaneous regression to relentless progression. We and 
others have identified different patterns of genetic change that 
underlie these disparate clinical behaviors (  2  ). One of the most 
characteristic genetic changes in neuroblastomas is deletion of the 
short arm of chromosome 1 (1p) (  3  ,  4  ). We have found the 1p dele-
tion in approximately 35% of all neuroblastomas and in 70%  –  80% 
of high-risk tumors (  5    –    11  ), suggesting the loss of a tumor suppres-
sor gene from this region. We analyzed more than 1200 neuro-
blastomas and mapped the smallest region of consistent deletion 
(SRD) to 1p36.31, from D1S2660 distally to D1S214 proximally 
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     Background     Neuroblastomas are characterized by hemizygous 1p deletions, suggesting that a tumor suppressor gene 
resides in this region. We previously mapped the smallest region of consistent deletion to a 2-Mb region 
of 1p36.31 that encodes 23 genes. Based on mutation analysis, expression pattern, and putative function, 
we identified CHD5 as the best tumor suppressor gene candidate.   
     Methods     We determined the  methylation status of the CHD5 gene promoter in NLF and IMR5 (with 1p deletion) 
and SK-N-SH and SK-N-FI neuroblastoma cell lines using methylation-specific sequencing and measured 
CHD5 mRNA expression by reverse transcription polymerase chain reaction in cells treated with or with-
out 5-aza-2-deoxycytidine, an inhibitor of DNA methylation. We transfected the cells with CHD5 and anti-
sense (AS) CHD5 DNA to assess the effect of CHD5 overexpression and suppression, respectively, on 
colony formation in soft agar and growth of xenograft tumors in athymic mice. We also analyzed the 
association of CDH5 expression with outcomes of 99 neuroblastoma patients. Statistical tests were 
two-sided.   
     Results     CHD5 expression was very low or absent in neuroblastoma cell lines. The CHD5 promoter was highly 
methylated in NLF and IMR5 lines, and CHD5 expression increased after treatment with 5-aza-2-
  deoxycytidine. Clonogenicity and tumor growth were abrogated in NLF and IMR5 cells overexpressing 
CHD5 compared with antisense CHD5 (clonogenicity: mean no. of colonies per plate, NLF-CHD5, 43 
colonies, 95% confidence interval [CI] = 35 to 51 colonies, vs NLF-CHD5-AS, 74 colonies, 95% 
CI = 62 to 86 colonies,   P <   .001; IMR5-CHD5, 11 colonies, 95% CI = 2 to 20 colonies, vs IMR5-CHD5-AS, 
39 colonies, 95% CI = 17 to 60 colonies,   P =   .01; tumor growth, n = 10 mice per group: mean tumor 
size at 5 weeks, NLF-CHD5, 0.36 cm 
3  , 95% CI = 0.17 to 0.44 cm  3  , vs NLF-CHD5-AS, 1.65 cm  3  , 
95% CI = 0.83 to 2.46 cm 
3  ,   P =   .002; IMR5-CHD5, 0.28 cm  3  , 95% CI = 0.18 to 0.38 cm  3  , vs IMR5-CHD5-AS, 
1.15 cm 
3  , 95% CI = 0.43 to 1.87 cm  3  ;   P =   .01). High CHD5 expression was strongly associated with 
favorable event-free and overall survival (  P   < .001), even after correction for   MYCN   amplification and 
1p deletion (  P   = .027).   
     Conclusions       CHD5   is the strongest candidate tumor suppressor gene that is deleted from 1p36.31 in neuroblastomas, 
and inactivation of the second allele may occur by an epigenetic mechanism.   
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(approximately 2 Mb) (  10  ,  12  ). The SRD that has been identified 
by most other groups who have mapped 1p deletions in neuroblas-
tomas overlaps this region (  13    –    21  ). Furthermore, the proximal 
and distal boundaries of this SRD are defined by three patients 
each (  10  ,  12  ), clearly establishing that this region contains at least 
one neuroblastoma tumor suppressor gene that is deleted from 
these tumors. 
  In a previous study (  12  ), we mapped 23 genes to the maximal 
SRD we deﬁ  ned on 1p36.31. We analyzed 30 neuroblastoma cell 
lines for mutations in these genes but found no examples of muta-
tional inactivation (ie, deletion, frameshift, or stop codon). We 
analyzed the expression of these 23 genes in neuroblastoma cell 
lines: seven had very low expression, two (  CHD5, RNF207  ) had 
virtually absent expression, ﬁ  ve had preferential expression in the 
nervous system, and seven had been previously associated with 
cancer pathogenesis (two with neuroblastoma). Only   CHD5   had all 
of these features (  12  ,  22  ). 
  In the current study, we hypothesized that   CHD5   was the best 
candidate tumor suppressor gene deleted from 1p36.31 in neuro-
blastomas. We assessed the methylation status of the promoter and 
determined whether methylation status was associated with the 
presence or absence of 1p deletion in neuroblastoma cell lines. We 
transfected   CHD5   into neuroblastoma cell lines and assessed the 
effect on both colony formation in soft agar (clonogenicity) and 
growth of xenograft tumors in athymic mice. We also compared 
the expression of 12 genes from the 1p36 SRD we deﬁ  ned with 
clinical and biologic risk factors in 101 neuroblastomas. Our goal 
was to determine whether   CHD5   is a bona ﬁ  de tumor suppressor 
gene and the likely target of the 1p36.31 deletions that character-
ize neuroblastoma. 
    Subjects and Methods 
    Patients 
  The 101 samples (91 from the Children’s Oncology Group [COG] 
and 10 from the Children’s Hospital of Philadelphia [CHOP]) that 
were used in this study were chosen to be representative of rigor-
ously defined clinical and biologic risk groups that were consistent 
with those used for COG but included additional genetic variables. 
The CHOP Institutional Review Board approved this study, and 
written informed consent was obtained before sample collection. 
The patient population is described in more detail elsewhere (  23  ). 
Briefly, for this study, low-risk patients were defined as infants 
(<1 year of age) with stage 1 or 2 disease by the International 
Neuroblastoma Staging System (INSS) (  24  ) and favorable biologic 
features. Intermediate-risk patients were almost all patients with 
INSS stage 3 disease who were older than 1 year. High-risk patients 
were defined as those with INSS stage 3 or 4 disease (only two had 
stage 3 disease) who were older than 1 year. High-risk patients were 
divided into two subsets: those without   MYCN   amplification (high 
risk) and those with   MYCN   amplification (ultrahigh risk). RNA was 
obtained from these 101 neuroblastoma tumors and subjected to 
microarray expression profiling using Affymetrix (Santa Clara, CA) 
U95A chips, as described (  23  ). Twelve of the 23 genes from the 
SRD were present on these chips (  AJAP1, NPHP4 KCNAB2, 
CHD5, RPL22, ICMT, ACOT7, HES2, TNFRSF25, KLHL21, 
THAP3,   and   CAMT1  ). 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Neuroblastoma is a childhood cancer that is characterized as hav-
ing genomic deletions at chromosome 1p. A neuroblastoma tumor 
suppressor gene may lie in this region, and based on previous 
studies,   CHD5   is a candidate.   
    Study design 
    CHD5   promoter methylation and expression in human neuroblas-
toma cell lines and effects of CHD5 overexpression on tumor 
growth in mouse models were assayed. Associations between 
CHD5 expression and clinical outcomes of 99 neuroblastoma 
patients were determined.   
    Contributions 
    CHD5   expression was low in the cell lines, and the   CHD5   promoter 
was highly methylated. Overexpression of   CHD5   slowed tumor 
growth in mouse models. CHD5 expression was strongly associ-
ated with increased event-free and overall survival of neuroblas-
toma patients.   
    Implications 
    CHD5   may be a neuroblastoma tumor suppressor gene, and its 
expression may be inhibited by promoter methylation.   
    Limitations 
  Other genes that are located in the region of the 1p deletions still 
need to be studied.     
    
  Tumor specimens from newly diagnosed patients were submit-
ted between September 1, 1993, and May 30, 2003, and the 
median follow-up time of patients who did not experience an event 
was 3.4 years. More speciﬁ  cally, 41 patients were younger than 
1 year and 60 were 1 year or older; 27 were stage 1 according to 
INSS, one patient was stage 2, 23 were stage 3, and 50 were 
stage 4. Of these 101 patients, 20 had   MYCN   ampliﬁ  cation, 48 
had favorable histology, 66 were hyperdiploid, 26 had 1p deletion, 
and 40 had 11q deletion. Twenty-eight were low-risk, 21 were 
intermediate-risk, 32 were high-risk (without   MYCN   ampliﬁ  ca-
tion), and 20 were ultrahigh-risk (with   MYCN   ampliﬁ  cation). 
Survival data were available for 99 of the 101 patients.   
    Cell Lines and Cell Culture 
  Neuroblastoma cell lines NLF, IMR5, SK-N-SH, SK-N-FI, 
CHLA-51, CHLA-79, CHLA-90, CHLA-123, CHLA-150, CHP-
134, CHP-901, CHP-902R, KCN, KCNR, LA-N-5, LA-N-6, 
NB69, NBL-S, NGP, NMB, SK-N-AS, SK-N-BE2, SK-N-DZ, 
and SMS-KAN were obtained from the CHOP cell line bank and 
grown in vitro under standard conditions (  10  ,  22  ,  25  ). We analyzed 
the neuroblastoma cell lines for promoter methylation: two with 
1p deletion (NLF and IMR5) and two without (SK-N-SH and SK-
N-FI). These cell lines were also used to study the effect of exoge-
nous CHD5 expression on in vitro growth, clonogenicity, and 
tumorigenicity. Cell growth in vitro was assessed by a colorimetric 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay. A multiwell scanner was used to measure the absor-
bance at 570  –  630 nm dual wavelengths. The untreated controls 
were assigned a value of 100%. Apoptosis was assessed by annexin 
V antibody and propidium iodide staining (Roche Molecular 
Biochemicals, Indianapolis, IN), according to the manufacturer’s 942   Articles | JNCI  Vol. 100, Issue 13  |  July 2, 2008
instructions as described previously (  26  ). Apoptosis was then 
monitored by flow cytometry analysis with a FACScan using 
CELLQuest software (Becton Dickinson, Mountain View, CA). 
For the studies of CHD5 re-expression using 5-aza-2-deoxycytidine, 
we plated 1    5 × 10  5   cells in 6-well plates, grew cells in the absence 
or presence of 5-aza-2-deoxycytidine (0.1  –  1.0   µ  M), and assessed 
cell morphology (cell size, shape, and neurite outgrowth), cell 
number measured by MTT assay, and CHD5 expression by real-
time reverse transcription  –    polymerase chain reaction (RT-PCR) 
after 0, 1, 4, and 7 days.   
    CHD5 RNA and Protein Expression 
  Genomic DNA and total RNA were isolated from the 24 neuro-
blastoma cell lines above, including NLF, IMR5, SK-N-SH, and 
SK-N-FI, using DNeasy and RNeasy kits (Qiagen, Valencia, CA), 
respectively. We analyzed CHD5 expression of these 24 lines by 
RT-PCR using CHD5 primers provided by the manufacturer 
(Hs00395930_m1) and the TaqMan Applied Biosystems 7900HT 
real-time RT-PCR system (Applied Biosystems Inc. (ABI), Foster 
City, CA). Expression of the glyceraldehyde-3-phosphate dehy-
drogenase gene using ABI primers (Hs4333764-famMGB) was 
used for normalization. We isolated RNA from the same 101 pri-
mary neuroblastoma samples described above and previously (  23  ). 
We used a commercially available panel of mRNAs that were derived 
from 17 normal tissues from Clontech (Mountain View, CA), and 
fetal brain RNA (Clontech) was used as a positive control. 
Expression profiling was performed on the Affymetrix U95Av2 
microarray (  23  ), and the data are freely available at the Gene 
Expression Omnibus (  http://www.ncbi.nlm.nih.gov/geo/  ). We 
measured differential gene expression based on 1p36 allelic status 
with the Patterns from Gene Expression (PaGE) algorithm (  27  ). 
  CHD5 protein expression in NLF and IMR5 parental and 
transfected lines was detected by immunoblotting with rabbit 
polyclonal anti-CHD5 antiserum (1    :    5000; Strategic Diagnostics, 
Inc., Newark, DE) and detected with donkey anti-rabbit poly-
clonal antiserum (Amersham Biosciences, Piscataway, NJ). Brieﬂ  y, 
nuclear pellets were vortexed several times in 0.42 M NaCl buffer 
with all protease inhibitors present. Samples were kept on ice at all 
times. Clear supernatants with nuclear proteins were collected 
after centrifuging extracts at 20 000 × g 10 minutes. Protein con-
centrations were determined by the Bradford method (Bio-Rad 
Laboratories, Hercules, CA). All extracts were prepared in dupli-
cate, and at least three independent experiments were conducted. 
Protein complexes were detected with CHD5 antibody and had a 
predicted molecular weight of 250  –  260 kDa (based on the amino 
acid composition), speciﬁ  cally in NLF and IMR5 cells that were 
transfected with   CHD5   in the sense orientation.   
    Promoter Methylation Analysis 
  DNA was isolated from NLF, IMR5, SK-N-SH, and SK-N-FI 
cells as described above after growing them in standard culture 
conditions for 1 week. We then treated DNA with sodium bisulfite 
(4 M) to convert all unmethylated cytosines to uracil, and we sub-
sequently amplified the modified DNA using RT-PCR as described 
previously (  28  ) with primers specific for modified DNA that were 
designed to encompass from     840 to +769 from the start of CHD5 
exon 1 (primer sequences are provided in Supplementary Table 1, 
available online). The amplified DNA was cloned using the TA 
cloning kit (Invitrogen, Carlsbad, CA) and sequenced using auto-
mated sequencing (ABI). We made six sets of primers in the CHD5 
promoter region (    840 to +769; CHD5 GenBank accession num-
ber AL031847) to survey for methylation status. PCR products 
were purified using agarose gel electrophoresis and the Qiagen 
purification kit (Qiagen, Valencia, CA) and were cloned using the 
pGEM-T Easy Vector System (Promega, Madison, WI). At least 
10 colonies were selected and sequenced to determine the percent 
methylation for each CpG. The percent methylation was deter-
mined by the number of clones with methylation of the given 
region (as determined by methylation-specific sequencing) divided 
by 10 and expressed as a percentage. All experiments were per-
formed in duplicate and repeated twice.   
    Clonogenicity and Tumor Growth Studies 
  We next performed clonogenicity assays by measuring colony 
formation in soft agar. Neuroblastoma cell lines NLF, IMR5, SK-
N-SH, and SK-N-FI were stably transfected with a CHD5 sense 
or antisense (AS) DNA (GenBank accession number AF425231) 
that had been cloned into the expression vector pcDNA3.1 
(Invitrogen, Carlsbad, CA). Expression of CHD5 was confirmed 
by RT-PCR analysis. Stable clones expressing CHD5 were 
selected and expanded and then seeded into T75 culture flasks and 
grown to 60%  –  70% confluency. Agar (0.35%) medium was 
  prepared by mixing regular DNA-grade agar and RPMI 1640 
with 10% fetal bovine serum (FBS); 1.5 mL was added to 60 mm 
wells. Cells were detached by incubation in trypsin-EDTA, cen-
trifuged at 350×  g  , and suspended (5 × 10  3   cells) in 0.25% low 
melting point agarose (Cambrex, Rockland, ME) that was 
dissolved in RPMI 1640 containing 10% FBS per well. Cells 
were then plated on the underlayer of 0.35% agar. Agar plates 
were incubated at 37°C for 3 weeks, at which time cell colonies 
were stained with 0.005% crystal violet (Sigma, St. Louis, MO) 
and scored using an inverted microscope. By convention, cell 
clusters measuring more than 500   µ  M in greatest diameter were 
considered a colony. Each soft agar assay was performed in tripli-
cate and repeated at least twice. 
  Stable neuroblastoma clones of NLF, IMR5, SK-N-SH, and 
SK-N-FI cells with either sense (-CHD5) or antisense (-CHD5-
AS) were suspended in Matrigel (BD Biosciences, San Jose, CA). 
Six-week-old female nu/nu mice (Charles River Laboratory, 
Wilmington, MA; n = 160 total; n = 10 in each group, two inde-
pendent experiments) were given subcutaneous injections of 1 × 
10  7   cells in the right ﬂ  ank. Tumor size (  L   × [  W  ] 
2   × 0.523/1000 = 
  x   cm  3  ) and body weight were measured once weekly. Mice were 
killed 5  –  6 weeks after injection, when the majority of mice that 
had been injected with tumors derived from cells transfected with 
CHD5-AS developed tumors that exceeded 3 cm  3  . Tumors were 
removed surgically, ﬁ   xed in 10% formalin, and stained with 
hematoxylin and eosin for histological examination. CHD5 
expression was conﬁ   rmed in the neuroblastoma xenografts by 
RT-PCR. This project was reviewed and approved by the 
CHOP Institutional Animal Care and Use Committee, and mice 
were housed and protocols were performed in accordance with 
institutional guidelines. Euthanasia was performed by the admin-
istration of ketamine (150 mg/kg) and xylazine (8 mg/kg) jnci.oxfordjournals.org    JNCI | Articles 943
intraperitoneally followed by cervical dislocation after deep anes-
thesia had been obtained.   
    Statistical Analysis 
  We analyzed associations between CHD5 mRNA expression and 
clinical factors by application of the two-sample   t   test or analysis of 
variance. Mean values for CHD5 expression are presented with 
95% confidence intervals. The distinction between high and low 
gene expression was based on the median value. We estimated 
event-free and overall survival probabilities by Kaplan  –  Meier anal-
ysis and compared survival distributions using a two-sided log-rank 
test. Time to event for event-free survival was defined as the time 
from diagnosis until the time of first occurrence of relapse, progres-
sion, or death, or until last contact if no event occurred. Time to 
event for overall survival was defined as the time from diagnosis 
until the time of death, or until last contact if the patient was still 
alive. We used Cox regression models to examine the prognostic 
significance of CHD5 expression, 1p deletion, and   MYCN   amplifi-
cation. The assumption of proportional hazards was checked using 
visual inspection of plots of the log-cumulative hazard vs log of 
survival time. All statistical tests were two-sided, and 
  P   values less than .05 were considered statistically significant unless 
otherwise indicated.     
    Results 
    CHD5 Expression and Promoter Methylation 
  CHD5 expression is restricted to neural tissues, and expression was 
very low or absent in all the neuroblastoma cell lines examined (  22  ). 
We previously examined   CHD5   for inactivating mutations in 30 
neuroblastoma cell lines but found only one missense mutation (  12  ). 
Thus,   CHD5   is not homozygously inactivated by deletion or muta-
tion with substantial frequency, so homozygous inactivation would 
require an epigenetic mechanism. Therefore, we investigated whether 
CHD5 expression was silenced by methylation in these lines. 
  We determined the methylation status of the CHD5 promoter 
in four cell lines—two with no CHD5expression (both with 1p 
deletion: NLF, IMR5) and two with low CHD5 expression (both 
without 1p deletion: SK-N-SH, S-KN-FI)—and in human fetal 
brain, which has high CHD5 expression. There were strong sites 
of methylation in NLF and IMR5 (60%  –  100%) between base pairs 
    780 to     450 and a secondary site between     400 and     340 bp 
(  Figure 1, A and B  ). The distal site showed much lower or no meth-
ylation in the two cell lines with low CHD5 expression (  Figure 1, 
C and D  ) or in human fetal brain (data not shown). We grew these 
lines in increasing concentrations of 5-aza-2-  deoxycytidine for up 
to 7 days and measured normalized CHD5 expression using 
   
  Figure 1    .       Methylation of the CHD5 promoter and 5  ′   coding region in four 
neuroblastoma cell lines.   A    –    B  ) CHD5 promoter methylation in NLF (  A  ) 
and IMR5 (  B  ) cells, both of which have hemizygous 1p deletions and 
virtually no CHD5 expression.   C    –    D  ) CHD5 promoter methylation in SK-
N-SH (  C  ) and SK-N-FI cells (  D  ), which lack 1p deletion and have low 
expression of CHD5. Methylation at a given GC dinucleotide, as deter-
mined by methylation-speciﬁ  c sequencing, is shown as a percentage of 
sequences analyzed (10 per site). Methylation was determined as the 
number of clones with methylation of the given region divided by 10 
and is expressed as a percentage.       944   Articles | JNCI  Vol. 100, Issue 13  |  July 2, 2008
  quantitative RT-PCR. A dose- and time-  dependent increase in 
expression was observed in all lines that was most dramatic (one to 
two orders of magnitude) in the two cell lines with 1p deletion and 
no CHD5 expression, compared with only two- to fourfold in the 
cell lines with readily detectable CHD5 expression (data not 
shown). Thus, there was a strong association between methylation 
of the distal promoter site and CHD5 expression, although no 
well-  established regulatory motifs were apparent. Moreover, these 
data suggest that this site contains an important regulatory domain 
and they support promoter methylation as a possible mechanism 
for epigenetic silencing of CHD5 transcription.           
    Suppression of Clonogenicity and Tumor Growth 
  We stably transfected CHD5 sense and antisense vectors into two 
neuroblastoma cell lines with 1p deletion and   MYCN   amplification 
(NLF and IMR5) and two with neither aberration (SK-N-SH and 
SK-N-FI). We examined the morphology, growth, differentiation, 
and apoptosis rates of these cell lines, but no major differences were 
observed (data not shown). We repeated these experiments under 
low serum conditions but again observed no major differences. 
  Next, we plated cells from CHD5-transfected and CHD5-AS  –
  transfected lines into soft agar. After 3 weeks of culture, NLF-
CHD5-AS clones formed statistically signiﬁ  cantly more colonies 
(mean = 74 large colonies per plate, 95% conﬁ  dence interval [CI] = 
62 to 86 colonies) than NLF-CHD5 clones (mean = 43 colonies, 
95% CI = 35 to 51 colonies (  P   < .001) (  Figure 2, A  ). Similarly, the 
IMR5-CHD5-AS control cells formed more colonies (mean = 39 
colonies, 95% CI = 17 to 60 colonies) than the CHD5-transfected 
cells (mean = 11 colonies, 95% CI = 2 to 20 colonies) (  P   = .01) 
(  Figure 2, B  ). However, there was no difference between the number 
of colonies formed by   CHD5  -transfected and   CHD5  -AS  –  trans-
fected clones of SK-N-SH (  P   = .16) and SK-N-FI (  P   = .1) (  Figure 2, 
C and D  ). Thus,   CHD5   expression caused a statistically signiﬁ  cant 
reduction in colony formation in the CHD5-expressing clones rela-
tive to the   CHD5  -AS clones, but only in cell lines with 1p deletion.         
  Next, we injected neuroblastoma cells stably expressing   CHD5   
or   CHD5  -AS into the ﬂ  anks of immunosuppressed nu/nu mice. 
Tumors became palpable within 1  –  2 weeks, but there was dramatic 
growth inhibition of   CHD5  -expressing clones for both NLF and 
IMR5 neuroblastoma cell lines compared with parental cell lines 
or   CHD5  -AS controls (  Figure 3, A and B  ). The mean tumor vol-
ume for NLF-  CHD5  -AS at 5 weeks after injection was 1.65 cm  3   
(CI = 0.83 to 2.46 cm  3  ), compared with 0.36 cm  3   (CI = 0.17 to 0.44 
cm  3  ) for NLF-  CHD5   (  P =   .002). The mean tumor size for IMR5-
  CHD5  -AS at 5 weeks after injection was 1.15 cm  3   (CI = 0.43 to 
1.87 cm  3  ), compared with 0.28 cm  3   (CI = 0.18 to 0.38 cm  3  ) for 
      Figure 2    .       Effect of altered CHD5 expression on clonogenicity in neuro-
blastoma cell lines. Plasmids containing CHD5 or antisense CHD5 
(CHD5-AS) were stably transfected into NLF and IMR5 neuroblastoma 
cell lines, both of which have hemizygous 1p deletion and   MYCN   ampli-
ﬁ  cation, and into SK-N-SH and SK-N-FI neuroblastoma cell lines, which 
have neither. Transfected cells were plated on soft agar, and colonies 
were counted 3 weeks later.   A  ) NLF cells. CHD5 vs CHD5-AS,   P   < .001. 
  B  ) IMR5 cells. CHD5 vs CHD5-AS,   P   = .001.   C  ) SK-N-SH cells. CHD5 vs 
CHD5-AS,   P   = .16.   D  ) SK-N-FI cells. CHD5 vs CHD5-AS,   P   = .10. Means 
and 95% conﬁ  dence intervals (  error bars  ) are shown.   P   values (two-
sided) were calculated using the Student   t   test. Data are representative 
of three independent experiments performed in quadruplicate.       
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IMR5-  CHD5   (  P   = .01). Both studies were repeated with similar 
results (data not shown). There was no statistically signiﬁ  cant dif-
ference in growth rates between   CHD5  - and   CHD5  -AS  –
    transfected SK-N-SH and SK-N-FI tumors (  Figure 3, C and D  ), 
again demonstrating the speciﬁ  city of tumor growth suppression 
for neuroblastoma lines with 1p deletion.          
  We also observed an effect on histology for the   CHD5  -
transfected tumors. The control tumors for NLF and IMR5 were 
undifferentiated with scant cytoplasm, as is typical of neuroblasto-
mas (  Figure 4, A  ). The NLF-  CHD5   tumors had areas of differentia-
tion and necrosis, whereas the IMR5-  CHD5    –  transfected tumors 
had a more elongated morphology (  Figure 4, A  ). We examined the 
mRNA expression of CHD5 in xenograft tumors derived from 
parental NLF and IMR5 cells, as well as the   CHD5  -transfected and 
  CHD5  -AS  –  transfected clones, by real-time RT-PCR. CHD5 
mRNA expression was higher in the   CHD5  -transfected clones than 
their respective parental lines (  Figure 4, B  ), and expression in 
  CHD5  -AS cells was intermediate. We also examined CHD5 protein 
expression in the NLF and IMR5 lines. The CHD5 protein (250  –
  260 kD) was detected only in the lines that were transfected with the 
  CHD5  -sense construct (  Figure 4, C  ). In summary, there was clear 
suppression of both clonogenicity and xenograft tumor growth of 
  CHD5  -transfected clones, but only in tumors with 1p deletion.           
    Association With Prognostic Features and Outcome 
  We analyzed microarray expression data from 101 neuroblastomas 
representing well-defined risk groups (low, intermediate, high, and 
ultrahigh) (  23  ) to assess clinical associations of candidate tumor 
suppressor gene expression from the SRD (  10  ,  12  ). Only 12 of the 
23 genes from the SRD were represented on the microarray chip, 
but these included   CHD5  , three other leading tumor suppressor 
gene candidates (  TNFRSF25  ,   CAMTA1  , and   AJAP1  ) (  12  ), and 
eight other genes. We compared expression patterns (high vs low) 
of all genes with clinical and biologic variables currently used in risk 
stratification of neuroblastoma patients, including patient age and 
INSS stage, as well as features of the tumor (  MYCN   amplification, 
1p deletion, 11q deletion, tumor cell DNA content/ploidy, Shimada 
histopathology). These features were also combined into risk 
groups, as described previously (  23  ,  29  ). 
  CHD5 expression had the strongest association with all eight 
clinical and biologic features (  Table 1  ). Expression of   ICMT  , 
  THAP3  ,   CAMTA1  ,   ACOT7, KCNAB2, RPL22,   and   KLHL21   
had weaker associations and/or associations with fewer variables 
(two to seven variables). Expression of   TNFRSF25   was associated 
with only one variable, and expression of the remaining three genes 
(  AJAP1  ,   NPHP4  ,   HES2  ) showed no statistically signiﬁ  cant associ-
ation with any of the variables. High CHD5 expression was strongly 
      Figure 3    .       Effect of CHD5 expression on tumor growth in neuroblas-
toma cell lines. NLF, IMR5, SK-N-SH, and SK-N-FI cells (10 
7   each) sta-
bly transfected with plasmids containing   CHD5  - or   CHD5  -AS were 
injected into the ﬂ  anks of nu/nu mice (n = 10 mice per group), and 
tumor growth was measured as volume weekly over 5 weeks. 
  A  ) NLF   CHD5  -AS vs NLF   CHD5  ,   P   = .002.   B  ) IMR5   CHD5  -AS vs IMR5 
  CHD5  ,   P   = .01.   C  ) SK-N-SH   CHD5  -AS vs SK-N-SH   CHD5  ,   P   = .07. 
  D  ) SK-N-FI   CHD5   vs SK-N-FI   CHD5  -AS,   P   = .26. Means and 95% 
conﬁ  dence intervals (  error bars  ) are shown. All   P   values (two-sided, 
comparisons at the 5-week time points) were calculated using a two-
sample Student   t   test. Data are representative of two independent 
experiments.       
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  associated with favorable clinical and biologic features: younger age 
(either <12 or <18 months), lower stage (1, 2, 4S vs 3 and 4), non-
ampliﬁ  ed    MYCN  , hyperdiploidy, favorable histopathology, and 
normal 11q (  Table 1  ) (  P   < .001 for all). CHD5 expression was also 
statistically signiﬁ   cantly lower in tumors with 1p deletion, and 
expression was inversely proportional to risk group (  Figure 5, A 
and B  ;   P   < .001). Together, these data strongly suggest that   CHD5   
is the tumor suppressor gene deleted from the 1p36 SRD.                 
  We compared event-free survival and overall survival for 99 of 
the 101 neuroblastoma patients based on the expression of 
      Figure 4    .       Histology and CHD5 expression in xenografts derived from 
NLF and IMR5 cells transfected with either CHD5 sense or CHD5 anti-
sense constructs.   A  ) Histology of NLF and IMR5 xenograft tumors (see 
  Figure 3  ) after 5 weeks of growth. NLF-  CHD5  -AS tumors were com-
posed of undifferentiated cells with scant cytoplasm (top left), 
whereas NLF-  CHD5   tumors showed areas of necrosis (  arrowheads  ) 
and differentiation (  arrows  ; top right). Cells in the IMR5-  CHD5  -AS 
tumors were undifferentiated (bottom left), whereas cells in the IMR5-
  CHD5   tumors had a more elongated appearance (bottom right). Bar = 
20   µ  m.   B  ) Relative expression of CHD5, normalized to glyceraldehyde-
3-phosphate dehydrogenase (GAPDH), was determined by real-time 
reverse transcription  –  polymerase chain reaction in parental NLF and 
IMR5 cell lines, as well as the CHD5 sense and CHD5 antisense trans-
fected lines used for the xenograft experiments. The normalized val-
ues indicated by each bar graph represent the mean of three 
measurements. Replicate measurements were within 10% of the 
mean for each bar shown.   C  ) Expression of CHD5 protein, as detected 
by immunoblotting, is shown for the NLF and IMR5 parental lines and 
the corresponding sense- and antisense-transfected cells used in 
these experiments.       
  Table 1  .         Association of candidate tumor suppressor gene expression with prognostic variables and outcome  *     
    Characteristic 
Gene 
  AJAP4   NPHP4   KCNAB2   CHD5   RPL22   ICMT   ACOT7   HES2   TNFRSF25   KLHL21   THAP3   CAMTA1     
    Age <12 mo NS   NS NS <.001 NS .007 NS NS NS NS .002 .004 
  Age <18 mo NS .013 .024 <.001 NS <.001 .008 NS NS NS <.001 <.001 
  INSS stage NS NS .046 <.001 NS .005 NS NS .033 NS <.001 <.001 
    MYCN   amplified .031 NS .009 <.001 .003 <.001 <.001 NS .008 NS .001 <.003 
  Ploidy NS NS .013 <.001 NS .001 NS NS .043 NS .006 .037 
  Shimada NS .010 .003 <.001 NS <.001 <.001 NS NS NS <.001 <.001 
  Risk group NS .019 .004 <.001 .006 <.001 .002 NS .012 NS <.001 <.001 
  1p deletion NS NS .018 <.001 NS <.001 .001 NS NS .002 <.001 <.001 
  11q deletion NS NS NS <.001 NS NS NS NS NS .003 NS .033 
  Log-rank-EFS NS NS .003 <.001 NS NS NS NS NS NS .041 .034 
  Cox-EFS NS NS .014 <.001 NS .035 NS NS .047 NS .032 .031 
  Cox-EFS    †   NS NS NS .007 NS NS NS NS NS NS NS NS 
  Cox-EFS    ‡   NS NS NS .010 NS NS NS NS NS NS NS NS 
  Cox-EFS  § NS NS NS .027 NS NS NS NS NS NS NS NS   
    *     Genes from the smallest region of deletion that were represented on the Affymetrix platform are shown in order from distal to proximal. For prognostic factors, 
associations with a   P   value of <.01 by two-sample   t   test were considered statistically significant (after a Bonferroni type correction). A   P   value of <.05 was con-
sidered statistically significant for the log-rank test and Cox regression analyses. NS = not significant; INSS = International Neuroblastoma Staging System (24); 
EFS = event-free survival. All statistical tests were two-sided.   
      †       Adjusted for   MYCN   amplification.   
      ‡       Adjusted for 1p deletion.   
    §     Adjusted for   MYCN   amplification + 1p deletion.     jnci.oxfordjournals.org    JNCI | Articles 947
  candidate tumor suppressor genes, with or without adjustment for 
1p deletion and   MYCN   ampliﬁ  cation.   CHD5   was the only gene 
whose expression was strongly associated with event-free survival 
in both univariate and multivariable analyses (  Table 1  ). Expression 
of the   KCNAB2  ,   CAMTA1  ,   THAP3  , and   TNFRSF25   genes was 
weakly associated with outcome by log-rank and/or Cox regres-
sion, but only in univariate analyses. High CHD5 expression was 
strongly associated with favorable event-free survival and overall 
survival (event-free survival: HR = 6.7, 95% CI = 2.8 to 16.1, and 
overall survival: HR = 7.1, 95% CI = 2.5 to 20.8; both   P   < .001; 
  Figure 5, C  ). Cox regression analysis showed that, after adjustment 
for CHD5 expression, 1p deletion was no longer statistically sig-
niﬁ   cantly associated with survival. Conversely, after including 
1p deletion or   MYCN   ampliﬁ  cation separately or jointly in the 
models, CHD5 expression remained statistically signiﬁ  cantly asso-
ciated with event-free survival (  P   = .027) (  Table 1  ). These results 
demonstrate that CHD5 expression is strongly associated with 
outcome in neuroblastomas,   CHD5   is the likely target of 1p dele-
tions in these tumors, and it may have a direct role in the biology 
and behavior of neuroblastomas.     
    Discussion 
  We previously identified 23 genes in the SRD on 1p36 (  10  ,  12  ) and 
sequenced every coding exon of these genes in 30 neuroblastoma 
cell lines (21 with 1p deletion). None of the genes showed evidence 
of homozygous genetic inactivation by deletion, frameshift, or 
inactivating mutation (  12  ). However, expression analyses and 
      Figure 5    .       Association of CHD5 expression with risk factors and outcome 
in primary neuroblastomas.   A  ) Normalized CHD5 expression in 101 pri-
mary neuroblastomas stratiﬁ   ed based on the presence (n = 26) or 
absence (n = 75) of 1p deletion (two-sample   t   test,   P   < .001).   B  ) 
Association of normalized CHD5 expression with the risk group (low, 
intermediate, high, and ultrahigh) as deﬁ  ned above and in (23). Brieﬂ  y, 
for this study, low-risk patients were deﬁ  ned as infants (<1 year of age) 
with stage 1 or 2 disease by the International Neuroblastoma Staging 
(INSS) system (24) and favorable biologic features. Intermediate-risk 
patients were almost all patients with INSS stage 3 disease who were 
older than 1 year. High-risk patients were deﬁ  ned as those with INSS 
stage 3 or 4 (only two had stage 3) disease who were older than 1 year. 
High-risk patients were divided into two subsets: those without   MYCN   
ampliﬁ  cation (high risk) and those with   MYCN   ampliﬁ  cation (ultrahigh 
risk). Twenty-eight were low-risk, 21 were intermediate-risk, 32 were 
high-risk (without   MYCN   ampliﬁ  cation), and 20 were ultrahigh risk (with 
  MYCN   ampliﬁ  cation) patients. Survival data were available for 99 of the 
101 patients. The association of CHD5 expression with risk group was 
assessed (analysis of variance,   P   < .001). The   box   stretches from the 
25th to 75th percentile. The median is shown with a   line   across the   box  . 
The   whiskers   extend to the highest and lowest observed values that are 
lower than and higher than 1.5 times the interquartile range from the 
third and ﬁ   rst quartile values. The   solid circles   are outlying values 
beyond the   whisker   edges.   C  ) Association of CHD5 expression with 
event-free survival in univariate analysis (log-rank,   P   < .001).   D  ) 
Association of CHD5 expression with overall survival in univariate 
analysis (log-rank,   P   < .001). HR = hazard ratio; CI = conﬁ  dence interval. 
All   P   values are two-sided.       
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  functional considerations suggested that   CHD5   was the most 
promising tumor suppressor gene candidate.   CHD5   was the only 
gene that had preferential expression in the nervous system (  12  ), 
virtually absent expression in neuroblastomas with 1p deletion, and 
prior implication in neuroblastoma pathogenesis (  22  ). We trans-
fected   CHD5   into several neuroblastoma cell lines, and there was a 
limited effect in vitro, yet we observed dramatic suppression of 
clonogenicity and tumorigenicity. This result suggests that   CHD5   
functions as a tumor suppressor gene and may be particularly 
important for anchorage-independent growth. Indeed, the phe-
nomenon of a limited effect on in vitro growth yet suppression of 
clonogenicity and in vivo tumorigenicity has been seen at times 
even with classical tumor suppressor genes, such as   RB1   and   TP53   
(  30    –    33  ). Furthermore, the chromatin remodeling function of 
  CHD5   is consistent with other tumor suppressor genes in human 
cancers, including   SMARCB1 (formerly known as INI1/SNF5  ) 
(  34    –    36  ),   SMARCA4 ( BRG1/hBRM  ) (  37  ,  38  ), and   BMI1   (  39    –    42  ). 
Thus, based on these analyses,   CHD5   emerged as the lead tumor 
suppressor gene candidate from the 1p36 SRD in neuroblastomas. 
  To provide additional evidence to support   CHD5   as a tumor 
suppressor gene, we analyzed the relationship of gene expression 
with prognostic variables, event-free survival, and overall survival 
for 12 of the 23 genes from the SRD in 101 neuroblastomas. Only 
six genes showed statistically signiﬁ  cant associations with three or 
more risk factors.   CHD5   expression showed the strongest associa-
tion with all eight clinical and biologic variables. High CHD5 
expression was also strongly associated with favorable outcome. 
Indeed, using Cox regression analysis, 1p deletion was no longer 
associated with outcome after correction for CHD5 expression. 
Conversely, the association between CHD5 expression and out-
come was retained even after correction for both   MYCN   ampliﬁ  ca-
tion and 1p deletion   (P   = .027). These data suggest that CHD5 
expression is a potent prognostic variable, that it likely plays a role 
in neuroblastoma pathogenesis, and that it may play a role even in 
some tumors without apparent 1p deletion. Our studies also dem-
onstrate that CHD5 expression is not just a surrogate marker for 
1p deletion because it was by far most strongly associated with 
outcome, and the expression of other genes tested from the SRD 
was weakly or not at all associated with outcome. More detailed 
studies will be required to determine whether addition of CHD5 
expression as a prognostic marker may more rigorously deﬁ  ned 
neuroblastoma risk groups. 
  Although we did not ﬁ  nd homozygous genetic inactivation of 
  CHD5   (  12  ), we did ﬁ  nd strong promoter methylation and tran-
scriptional silencing of the remaining allele in 1p-deleted neuro-
blastoma lines compared with lines without 1p deletion or with 
fetal brain tissue. This epigenetic mechanism could inactivate 
expression or lower it sufﬁ  ciently to functionally silence the gene. 
Indeed, there is precedent for transcriptional silencing by methyla-
tion to inactivate the second allele of other tumor suppressor 
genes, including   RASSF1A   (  43  ,  44  ) and   OPCML   (  45  ). Also,   CHD5   
could be re-expressed by growing these cells in 5-aza-2-
  deoxycytidine, so this approach may have utility in treating neuro-
blastomas with low or absent CHD5 expression. 
  We now have convincing evidence that   CHD5   is the tumor 
suppressor gene deleted from the 1p36.31 SRD in neuroblastomas. 
It is difﬁ  cult to prove unequivocally that no other gene from the 
SRD or elsewhere on 1p36 contributes to the pathogenesis of 
neuroblastomas. However, within this SRD,   CHD5   is the only 
gene that fulﬁ   lls all tumor suppressor gene criteria. We ﬁ  rst 
described   CHD5   as a novel member of this chromatin remodeling 
gene family that was consistently deleted from 1p36 in neuroblas-
tomas and as a candidate tumor suppressor gene (  22  ). Recently, 
Bagchi et al. (  46  ) took an independent approach using chromo-
some engineering to generate mouse models with gain and loss of 
a region corresponding to the region of human 1p36 that con-
tained mouse   Chd5  . They identiﬁ  ed m  Chd5   as a gene that controls 
proliferation, apoptosis, and senescence via the p19Arf/p53 path-
way. Their results also suggest that gene dosage is tightly regulated 
and that homozygous deletion of   Chd5   in tumors is rarely seen, 
which is consistent with our ﬁ  nding that homozygous genetic inac-
tivation of   CHD5   is rare in human neuroblastomas. Furthermore, 
their independent identiﬁ  cation of   Chd5   as a tumor suppressor 
gene in a mouse model supports our ﬁ  ndings in human neuroblas-
tomas and suggests that   CHD5   may have a role in the pathogenesis 
of other human cancers characterized by 1p36 deletions. Future 
studies will determine whether the primary consequence of mouse   
  Chd5   inactivation is through p19Arf/p53 and/or other pathways in 
these tumors. 
  This study has potential limitations. Only 12 of the 23 genes 
from the SRD were represented on the expression proﬁ  ling micro-
array so we were unable to assess associations between clinical 
outcomes with expression of 11 of the genes in the SRD. 
Nevertheless, the four genes that were the most promising candi-
dates, including   CHD5  , were all included on the microarray. It was 
beyond the scope of this project to transfect full-length cDNAs of 
all 23 genes from the SRD into neuroblastoma cell lines with and 
without 1p deletion and to assess effects on growth, clonogenicity, 
and tumorigenicity. However, 10 of the genes from this region 
were tested in the study by Bagchi et al. (  46  ), and only   CHD5   was 
able to restore growth control.         
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